ReviewMultiple sclerosis (Houndmills, Basingstoke, England)2026
Induced pluripotent stem cell treatment for microglia replacement in progressive MS.
Review in Multiple sclerosis (Houndmills, Basingstoke, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundInduced pluripotent stem cells (iPSCs) offer a novel approach to target microglia, key drivers of multiple sclerosis (MS) pathology. A promising therapeutic strategy involves depleting resident microglia using colony-stimulating factor 1 receptor (CSF-1R) inhibitors, followed by differentiating iPSCs into microglia in vitro and transplanting them into the central nervous system (CNS). However, no studies have yet specifically examined iPSC-derived microglial replacement in MS.
objectivesThis review evaluates the feasibility of replacing pathogenic microglia in MS with iPSC-derived microglia.
methodsA systematic literature search identified studies on microglial depletion, iPSC differentiation into microglia, and transplantation, as well as reports involving other MS-relevant neural cell types.
resultsDirect studies on iPSC-derived microglia transplantation in MS are currently lacking; however, several preclinical investigations using iPSC-derived neural stem cells and oligodendrocyte precursor cells in animal models demonstrate robust engraftment, targeted migration to demyelinated lesions, reduced inflammation, enhanced remyelination, and significant functional recovery in vivo. These findings, besides microglia-specific transplantation, depletion, and repopulation studies in other disease contexts, support the biological plausibility of iPSC-based CNS cell replacement and inform future microglial transplantation research.
conclusionReplacing pathogenic microglia with iPSC-derived counterparts represents an emerging therapeutic avenue for progressive MS. Rigorous preclinical studies are needed to confirm safety, optimize transplantation, and evaluate long-term efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.